Kyntra Bio (NASDAQ:KYNB) Now Covered by Analysts at Rodman & Renshaw

Equities researchers at Rodman & Renshaw began coverage on shares of Kyntra Bio (NASDAQ:KYNB) in a research note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $30.00 price target on the stock. Rodman & Renshaw’s price target indicates a potential upside of 352.49% from the company’s current price.

A number of other equities research analysts have also weighed in on KYNB. HC Wainwright upgraded shares of Kyntra Bio to a “strong-buy” rating in a report on Friday, February 27th. Wall Street Zen upgraded shares of Kyntra Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.00.

Kyntra Bio Stock Down 1.2%

KYNB stock opened at $6.63 on Tuesday. Kyntra Bio has a 1 year low of $4.85 and a 1 year high of $12.60. The company has a market cap of $26.85 million, a PE ratio of 0.16 and a beta of 1.01. The stock’s 50-day moving average is $7.00.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC bought a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio as of its most recent SEC filing. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.